Annovis Bio Q2 net loss $0.32/sh; cash $17.1M; Phase 3 AD trial advances with 38 patients randomized

Annovis Bio, Inc.

2025-Q2 EPS reported -$0.64

Cash and cash equivalents $17.1M as of June 30, 2025, up from $10.6M at Dec 31, 2024.
Net loss per share $0.32 (basic/diluted) for Q2 2025 vs $0.44 in Q2 2024.
Phase 3 early AD trial: 38 patients randomized, nearly 200 in screening, 76 U.S. sites (46 enrolling).
R&D expenses $5.2M, G&A $1.1M, both down YoY.
Transferred all patent families to crystal buntanetap, achieving comprehensive global IP coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.